Skip to content

Author

P. Ridker

We have 6 of 103 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Interleukin-6 predicts cardiovascular events beyond standard modifiable risk factors in individuals without atherosclerotic cardiovascular disease

Current risk stratification algorithms capture high-risk individuals with classical risk factors or established atherosclerotic cardiovascular disease (ASCVD). However, a clinically relevant proportion of individuals without threshold levels of standard modifiable risk factors (SMuRF) – namely hypertension, dysli...

F. Kahles, B. Kurt, K. Schneider et al. · 0 citations
Open access Oct 2026

Longitudinal high-sensitivity C-reactive protein assessment predicts cardiovascular risk in apparently healthy individuals

High-sensitivity C-reactive protein (hsCRP) is the guideline-recommended biomarker for assessment of residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD). Clinical adoption remains limited, especially in individuals without established ASCVD. This study used longitudinal measurements to ev...

B. Kurt, M. Reugels, K. Schneider et al. · 0 citations
Open access Oct 2026

Prognostic impact of high-sensitivity C-reactive protein trajectories and sustained residual inflammation for prediction of cardiovascular outcomes

Traditional risk factors for atherosclerotic cardiovascular disease (ASCVD) fail to fully reflect the residual risk, driven by chronic low-grade inflammation, observed in many. Generally, high-sensitivity C-reactive protein (hsCRP) concentrations remain stable, but some individuals may experience increases. More...

F. Kahles, M. Reugels, K. Schneider et al. · 0 citations
Open access Aug 2026

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

BACKGROUND: In SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), among 17 604 patients with known atherosclerotic cardiovascular disease and overweight or obesity, but not diabetes, randomization to the glucagon-like peptide-1 receptor agonist semaglutide significantly red...

Jorge Plutzky, P. Bogdański, H. Colhoun et al. · 1 citation
Review Sep 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes

Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...

Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.